SynthesisCatheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions2025
Long-Term (5-Years) Outcomes of Current Drug-Eluting Stents in Percutaneous Coronary Intervention: A Network Meta-Analysis of Randomized Controlled Trials.
Synthesis in Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Small-Vessel Coronary Disease and Drug-Coated Balloons: Time to Reconsider Our Strategy?Arquivos brasileiros de cardiologia · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundVarious drug-eluting stents (DES) are currently used for percutaneous coronary intervention (PCI). However, long-term trials reveal inconsistent results in head-to-head comparisons.
aimsTo conduct a network meta-analysis of relevant trials to assess the performance of different DES currently used in PCI.
methodsWe systematically searched major databases for randomized controlled trials (RCTs) reporting 5-year outcomes of currently used DES and conducted a network meta-analysis using a frequentist random-effects model with odds ratios (ORs) as effect measures. DES were ranked by P-scores across several outcomes, with definite/probable stent thrombosis as the primary outcome. Statistical analyses were conducted in R software (v4.4.1), with significance set at p < 0.05.
resultsTwenty-nine RCTs involving 46,502 patients were included in the analysis. Six currently used DES-Orsiro, Xience, Resolute, Nobori/BioMatrix, Synergy, and Promus-were analyzed. All comparisons showed nonsignificant results for outcomes at 5-year follow-up. Synergy ranked highest for definite/probable stent thrombosis (p = 0.85), all-cause mortality (p = 0.76), cardiac death (p = 0.87), and target vessel revascularization (p = 0.91). Promus ranked best for any myocardial infarction (MI) (p = 0.86), target lesion revascularization (p = 0.93), and target vessel-related MI (p = 0.73). Nobori/BioMatrix ranked highest for target lesion failure (p = 0.80). The newer generation Biofreedom stent also showed nonsignificant results but was excluded from the main analysis due to the availability of 5-year outcomes from only one study. Global and local inconsistencies were nonsignificant for all outcomes and comparisons.
conclusionThe analysis revealed no significant differences in 5-year outcomes among the various DES. However, Synergy and Promus performed best for key outcomes such as stent thrombosis, mortality, and MI, suggesting their potential for favorable performance in clinical practice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.